Nivocup: An Open-Label Phase Ii Study On The Efficacy Of Nivolumab In Cancer Of Unknown Primary.

Junko Tanizaki,Kan Yonemori,Kohei Akiyoshi,Hironobu Minami,Hiroki Ueda,Yuichi Takiguchi,Chihiro Nakayama Kondoh,Yoshihiko Segawa,Shin Takahashi,Yasuo Iwamoto,Yasuhiro Kidera,Kazuya Fukuoka,Yasushi Nakamura,Yasutaka Chiba,Kazuto Nishio,Kazuhiko Nakagawa,Hidetoshi Hayashi

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 10|浏览36

暂无评分

摘要

106Background: CUP has a poor prognosis with a median survival of less than 12 months. Given the recent approval of immune checkpoint inhibitors in several cancer types, we performed a multicenter ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要